Clinical Trial

CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance

Completed
View on ClinicalTrials.gov →
Summary
The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time glucose data with the use of a continuous glucose monitor (CGM) in obese patients with impaired glucose tolerance will improve adherence to lifestyle modifications. As a result, a decrease in body mass index (BMI) is expected with subsequent improvement in insulin sensitivity, thus reducing risk of obesity-related complications later in childhood/adolescence and adulthood.
Protocol Amendment History 3 changes
critical Trial completed 2026-08-08
notable Enrollment reduced: 15 -> 12 participants 2026-08-08
minor Completion moved earlier: 2026-12 -> 2026-06-25 2026-08-08
Trial Details
NCT Number NCT05387551
Lead Sponsor Nemours Children's Clinic
Conditions Impaired Glucose Tolerance, Prediabetes
Enrollment 12 participants
Start Date 2022-12-01
Primary Completion 2026-06-25 (estimated)
Study Completion 2026-06-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-07